fluorouracil + heparin

Fluorouracil + heparin is a combination of two pharmaceutical agents used primarily in the context of portal vein infusion chemotherapy, particularly as an adjuvant therapy following curative resection for pancreatic cancer. Fluorouracil (5-FU) is a pyrimidine analog antimetabolite that inhibits DNA synthesis by blocking thymidylate synthetase, thereby interfering with cell proliferation and exerting antineoplastic effects[2]. Heparin is an anticoagulant that enhances the activity of antithrombin III to inhibit thrombin (factor IIa) and factor Xa, reducing blood clot formation[3]. The combination has been studied for its potential to prevent liver metastasis and improve survival rates post-surgery by delivering chemotherapy directly into the portal circulation while preventing catheter-related thrombosis[1].

Other names

5-fluorouracil + heparin5-FU + heparin